Patients must meet all of the following criteria to be eligible for the study:

1. Signed Informed Consent Form available

2. Patients* = 18 years of age at time of signing Informed Consent Form

3. Confirmed hepatocellular carcinoma diagnosis based on histopathological findings from tumor tissue or typical diagnostic imaging on dynamic CT or MRI according to AASLD criteria.

4. Intermediate stage HCC as defined by the following criteria:
- Disease not amenable to curative surgery, liver transplantation or curative ablation BUT disease amenable to TACE at enrollment as judged by the investigator.
- No massive multinodular pattern preventing adequate TACE
- No tumor of a diffuse infiltrative HCC type (hypovascular infiltrative tumors with ill-defined borders)
- Patent portal vein flow
- No main portal vein invasion/thrombosis on baseline/eligibility imaging. Patients with minimal invasion, (Vp1 and Vp2) may be eligible if no exclusion criteria are violated.
- No extrahepatic disease

Note: Patients with HCC beyond Milan criteria who enter a downstaging protocol may be recruited into the trial if they do not present any exclusion criteria.

5. Patients with recurrence after resection/ablation or after previous TACE are eligible, if they – according to the investigator – have an indication for (additional) TACE

6. Child-Pugh score class A or B7 without ascites requiring more than 100 mg of spironolactone/day (see exclusion criteria) at enrollment.

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 at enrollment.

8. Adequate organ and bone marrow function

9. Life expectancy of = 3 months

10. The following laboratory values obtained less than or equal to 7 days prior to randomization.
- Total bilirubin = 3.0 x the upper limit of normal (ULN)
- Urine dipstick for proteinuria = 2+ (within 7 days prior to randomization)
Patients discovered to have = 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate < 1 g of protein in 24 hours
- The following other laboratory values measured within 7 days prior to randomization are either normal or if abnormal do not represent a medical contraindication for TACE and
atezolizumab/bevacizumab as judged by the investigator: Platelet count, hemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum creatinine, INR or aPTT, alkaline
phosphatase, neutrophil count (ANC), and serum albumin.

11. Negative serum pregnancy test done lesser than or equal to 7 days prior to randomization, for females of childbearing potential only.

12. No presence of untreated or incompletely treated varices with bleeding or high-risk for bleeding: Availability of esophagogastroduodenoscopy (not older than 6 months) in which all size of varices (small to large) had been assessed and varices were treated per local standard of care prior to randomization.

13. Absence of other severe comorbidities

14. Resolution of any acute, clinically significant treatment-related adverse events from prior therapy/procedure to Grade = 1 prior to randomization, with the exception of alopecia.

15. For patients with active hepatitis B virus (HBV):
- HBV DNA = 2000 IU/mL obtained within 28 days prior to randomization, AND
- Anti-HBV treatment (per local standard of care; e.g., entecavir) for a minimum of 14 days prior to randomization and willingness to continue treatment for the length of the study.

16. For patients with active hepatitis C virus (HCV):
- Patients positive for hepatitis C virus (HCV) antibody are eligible, also if polymerase chain reaction testing is positive for HCV ribonucleic acid (RNA).
- However, anti-viral therapy against HCV is only allowed prior to trial but not during the trial.
- For HBV and HCV co-infection refer to exclusion criterion 11.

17. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for at least 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 1 month after the last TACE procedure.
- A woman is considered to be of childbearing potential if she is postmenarcheal, has not reached a postmenopausal state (= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).
- Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing
intrauterine devices, and copper intrauterine devices.
- The reliability of sexual abstinence should be evaluated in relation
to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

18. For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as defined below:

- With female partners of childbearing potential, men must remain abstinent or use a condom plus an additional contraceptive method that together result in a failure rate of < 1% per year during the treatment period and for 6 months after the last dose of bevacizumab or 1 month after the last TACE procedure. Men must refrain from donating sperm during this same period.

- With pregnant female partners, men must remain abstinent or use a condom during the treatment period and for 6 months after the last dose of bevacizumab or 1 month after the last TACE procedure to avoid exposing the embryo.

- The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar,
ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.

*There are no data that indicate special gender distribution. Therefore, patients will be enrolled in the study gender-independently.

Patients who meet any of the following criteria will be excluded from study entry:

1. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC (only if proven by biopsy).

2. Previous treatment with atezolizumab or bevacizumab.

3. Previous treatment with a programmed death 1 (PD1), programmed death-ligand (PD-L1), or cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, or any form of cancer immunotherapy for HCC.

4. Clinically meaningful ascites, defined as ascites requiring non-pharmacologic intervention (e.g. paracentesis) to maintain symptomatic control.

- Patients with ascites requiring pharmacologic intervention (e.g. diuretics) and stable for = 2 months on low doses of diuretics (spironolactone 100 mg/d or equivalent) for ascites are eligible.
Of note, diuretics for other indications such as congestive heart failure are not considered in this regard.

5. Major surgical procedure, open biopsy, or significant traumatic injury = 28 days prior to randomization or anticipation of need for major surgical procedure during the course of the study or non-recovery from side effects of any such procedure.

6. Significant cardiovascular disease, such as cardiac disease (New York Heart Association Class II or greater), myocardial infarction or cerebrovascular accident within 3 months prior to randomization, as well as unstable arrhythmias (note: beta blockers or digoxin are permitted), unstable angina, new-onset angina (begun within the last 3 months).

7. Uncontrolled hypertension defined by a systolic blood pressure (BP) = 150 mmHg or diastolic blood pressure (BP) = 100 mmHg, with or without antihypertensive medication. Prior history of hypertensive crisis or hypertensive encephalopathy. Patients with initial blood pressure (BP) elevations are eligible if initiation or adjustment of antihypertensive medication lowers pressure to meet entry criteria.

8. Current or recent (within 10 days prior to study treatment start) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purpose (prophylactic anticoagulation permitted, e.g. new oral anticoagulants [apixaban, dabigatran, rivaroxaban], LMW heparin, ASA up to 300 mg/qd).

9. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism = 6 months prior to randomization.

10. With regards to eligibility for adequate TACE, patients presenting with either of the following conditions are excluded:

- Past history of bilioenteric anastomosis or biliary procedure (e.g., endoscopic papillotomy or biliary stenting) or patients with aerobilia

- Central biliary obstruction (right or left intrahepatic duct, common hepatic duct, common bile duct)

- Celiac occlusion

11. Any ongoing infection > grade 2 NCI-CTCAE version 5.0. Note on HIV, HBV, and HCV infection: also consider inclusion criteria s 15, 16, and exclusion criterion 18. Patients with co-infection for HBV and HCV are excluded, unless tested negative for HCV RNA by PCR.

12. Patients with seizure disorder requiring medication.

13. Prior allogeneic bone marrow transplantation or prior solid organ transplantation.

14. Evidence or history of bleeding diathesis or any hemorrhage or bleeding event > CTCAE grade 3 within 4 weeks prior to randomization.

15. Non-healing wound, ulcer, or bone fracture.

16. Renal failure requiring hemo- or peritoneal dialysis.

17. Known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation including a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein; known hypersensitivity to Chinese hamster ovary cell products or to any component of the atezolizumab or bevacizumab formulation.

18. Positive test for human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS), with the following exception: patients with a positive HIV test at screening are eligible, provided they are stable on anti retroviral therapy, have a CD4 count > 200 cells/µL, and have an undetectable viral load.

19. Active tuberculosis

20. Interstitial lung disease with ongoing signs and symptoms at the time of informed consent.

21. History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, idiopathic pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computed tomography (CT) scan

Note: History of radiation pneumonitis within the radiation field (fibrosis) is permitted.

22. Persistent proteinuria of CTCAE Grade 3 or higher (> 3.5 g/24 hrs, measured by urine protein: creatinine ratio on a random urine sample).

23. Pregnant or nursing women

24. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.

25. Active or history of autoimmune disease including, but not limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener’s granulomatosis, Sjögren syndrome, Guillain-Barre syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.

Note: History of autoimmune-mediated hypothyroidism on a stable dose of thyroid replacement hormone, or controlled Type 1 diabetes mellitus on a stable insulin regimen may be eligible based on consultation with the sponsor’s medical monitor.
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:

- Rash must cover < 10% of body surface area

- Disease is well controlled at baseline and requires only low-potency topical corticosteroids

- No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high potency or oral corticosteroids within the previous 12 months,

26. Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-TNF-alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during study treatment, with the following exceptions:

- Patients who received acute, low-dose systemic immunosuppressant medication or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of corticosteroids for a contrast allergy) are eligible for the study.

- Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.

27. Use of any herbal remedies known to interfere with the liver or other major organ functions. Patients must notify the investigator of all herbal remedies used during the study.

28. Administration of a live, attenuated vaccine within four weeks prior to start of enrollment, or anticipation that such a live attenuated vaccine will be required during the study or within 5 months after the last dose of atezolizumab, 6 months after the last dose of bevacizumab, or 1 month after the last TACE procedure.

29. History of malignancy other than HCC within 3 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or death (e.g. 5-year OS rate > 90%), such as adequately treated carcinoma in situ of the cervix, non melanoma skin carcinoma, localized prostate cancer, ductal carcinoma in situ, or Stage I uterine cancer. Other similar cases can be considered after discussion with lead investigators and sponsor.

30. Receipt of an investigational drug within 28 days prior to initiation of study drug

31. Patient with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent or patients with substance abuse, medical, psychological or social conditions that may interfere with the patient’s participation in the study or evaluation of the study results.

Subjects meeting all of the following criteria will be considered for admission to the clinical trial:

1. Subjects must be = 18 years at the time of screening.

2. Confirmed HCC (either by imaging in a cirrhotic liver [liver lesions that show typical features of HCC on IV contrast-enhanced CT or MRI scans, i.e., hypervascularity in the arterial phase with washout in the portal or the late venous phase] or histopathologically from biopsy specimen or surgery).

3. Disease not amenable to resection, liver transplantation or loco-regionary therapy, such as curative ablation, trans-arterial chemoembolization (TACE) or transarterial radio-embolization (TARE).

4. Eligible for therapy with Atezolizumab / Bevacizumab according to standard of care.

5. Measurable disease per RECIST 1.1.

6. Preserved liver function with a Child-Pugh score A or B (maximally 7 points).

7. Performance status ECOG 0-1.

8. Available CT scan of thorax and MRI or CT scan of abdomen with contrast agent not older than 30 days before start of treatment (A/B C1d1).

9. Documented virology status of hepatitis, as confirmed by screening HBV and
HCV serology test

10. For patients with active HBV: HBV DNA < 500 IU/ml obtained within 28 days prior to initiation of study treatment and anti-HBV treatment per local standard of care for a minimum of 14 days prior to study entry and willingness to continue treatment for the length of the study

11. For patients with active HCV infection (as characterized by the presence of de
tectable HCV RNA): must be managed per local institutional practice for the
length of the study.

12. Adequate organ and marrow function measured within 72 hours prior to randomization as follows:
a. Hemoglobin = 8 g/dL
b. Absolute neutrophil count = 1.0 x 10^9/L
c. Platelet count = 50 x 10^9/L
d. Total bilirubin = 3.0 x the upper limit of normal (ULN)
e. Alanine aminotransferase (ALT) and aspartate aminotransferase = 5 x ULN
f. International normalized ratio = 1.6.
g. Calculated creatinine clearance = 30 mL/min as determined by Cockroft Gault

13. Women of child-bearing potential (WOCBP) must agree to use, and be able to comply with, highly effective contraception (</= 1% failure rate annually, see Appendix 5: CTFG Recommendation Birth control methods) without interruption prior to starting therapy with A/B, while on treatment with A/B and for a period of 6 months after the last dose treatment with A/B.

14. WOCBP must have a negative serum pregnancy test (beta-HCG) result at screening and agree to ongoing pregnancy testing during the course of the trial.

15. Male subjects must practice true abstinence or agree to use a condom during sexual contact with WOCBP while participating in the trial.

16. Ability of subject to understand character and individual consequences of clinical trial and to comply with the study protocol and dosing regimen.

17. Written informed consent (must be available before enrolment in the clinical trial)

18. Subject willing to undergo tumor biopsy. This requires a tumor lesion accessible for a biopsy.

Subjects presenting with any of the following criteria will not be included in the clinical trial:

1. Use of immunosuppressive medication within 6 months prior to the first dose of Atezolizumab / Bevacizumab. The following are exceptions to this criterion:
a. Intranasal, inhaled, topical steroids or local steroid injections (e.g. intraarticular injection).
b. Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or equivalent
c. Steroids as premedication for hypersensitivity reactions or as an antiemetic.

2. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease, diverticulitis, systemic lupus erythematosus, sarcoidosis, granulomatosis with polyangiitis, Graves’ disease, rheumatoid arthritis, hypophysitis, uveitis, autoimmune pneumonitis, autoimmune myocarditis, etc.).

The following are exceptions to this criterion:
a. Subjects with vitiligo or alopecia.
b. Subjects with hypothyroidism stable on hormone replacement.
c. Any chronic skin condition that does not require systemic therapy.
d. Subjects with coeliac disease controlled by diet alone.
e. Subjects without active disease in the last 5 years may be included but only after consultation with the study clinical lead.

3. Prior exposure to immune-mediated therapy including, but not limited to, other anti-CTLA-4, anti-PD-1, anti-PD-L1, and anti-VEGF antibodies.

4. Known to have tested positive for human immunodeficiency virus (HIV) infection.

5. Co-infection of HBV and HCV. Subjects with a history of HCV infection but who are negative for HCV RNA by PCR will be considered non-infected with HCV.

6. Evidence by investigator assessment of varices at risk of bleeding on upper endoscopy undertaken within 12 months of randomization.

7. Refractory nausea and vomiting, chronic gastrointestinal disease, inability to swallow a formulated product, or previous significant bowel resection that would preclude adequate absorption, distribution, metabolism or excretion of investigational product.

8. Uncontrolled arterial hypertension defined by a systolic pressure > 150 mm Hg or diastolic pressure > 90 mm Hg or other hypertensive cardiovascular complications despite standard medical treatment.

9. Any history of nephrotic or nephritic syndrome.

10. Usage of systemic antibiotic therapy within 2 weeks prior to the first dose of Atezolizumab/Bevacizumab (C1d1).

11. Usage of probiotic products/supplements within 1 week prior to the first dose of Atezolizumab/Bevacizumab (C1d1).

12. Known fibrolamellar HCC, sarcomatoid HCC, infiltrative-type HCC, or mixed cholangiocarcinoma and HCC.

13. History of another primary malignancy. Exceptions include:
a. malignancy treated with curative intent or has low potential risk for recurrence with no known active disease = 5 years before the first dose of study intervention;
b. malignancy which occurred < 5 years before the first study intervention, is not active, and not expected to recur or be clinically relevant in the next 2 years.

14. Receipt of live attenuated vaccine within 30 days prior to the first dose of study intervention.

15. Pregnancy or lactation.

16. History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.

17. Participation in other interventional clinical trials or observation period of competing clinical trials, respectively.

18. Held in an institution by legal or official order.

19. Legally incapacitated.

20. Known hypersensitivity to any component of the vancomycin, atezolizumab or bevacizumab formulation.

- Ability to understand and willingness to sign a written informed consent document.

- Histologically confirmed FL-HCC or other malignant disease that is locally advanced and inoperable or metastatic.

- Non-FL-HCC patients can be included

- in case of disease progression after therapy and fulfilling at least one of the following criteria
i. no further standard therapy is available.
ii. patient is considered unsuitable for further available standard therapy.
iii. patient is unwilling to receive treatment with available standard therapy.

- if no standard therapy exists.

- Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-based NGS or RT-PCR.

- Age = 18 years.

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

- Patients must have measurable disease per iRECIST.

- Negative SARS-CoV-2 rapid antigen test (as long as WHO declares pandemic spread of SARS-CoV-2).

- Adequate organ function laboratory values
1. Absolute Lymphocyte Count > 500/µl
2. Platelets > 50.000/µl
3. Creatinine clearance GFR > 30 ml/min
4. Liver function Child-Pugh index class A or B7
5. Alanine aminotransferase (ALT) and aminotransferase (AST) = 5 times upper limit range
6. Bilirubin = 3 mg/dl

- Negative serological Hepatitis B test or negative PCR in case of positive serological test without evidence of an active infection, negative testing of Hepatitis C RNA, negative HIV test within 6
weeks prior to study inclusion.

- Female patients of child bearing potential (FCBP) and male patients with partners of child bearing potential, who are sexually active, must agree to the use of two effective forms (at least one
highly effective method) of contraception. This should be started from the signing of the informed consent and be continued until 5 months (both female and male patients) after last dose of an
IMP (Atezolizumab (TecentriqTM) or vaccination).

- For FCBP two negative pregnancy tests (sensitivity of at least 25 mIU/mL) prior to first application of a study drug (vaccination at visit V1), one at screening and the other one at visit V1 prior
(< 24h) to first vaccination.

- Postmenopausal or evidence of non-child-bearing status.

- Pregnant or breastfeeding.

- Unwilling or unable to follow the study schedule for any reason.

- Chemotherapy or other systemic therapy or radiotherapy, up to 14 days prior to the first dose of study drug.

- Concurrent or previous treatment within 30 days in another interventional clinical trial with an investigational anticancer therapy or any other investigational therapy, which would interfere with the study s primary and secondary endpoints.

- Major surgery within 28 days of dosing of study drug.

- Have not recovered from adverse events to grade = 2 or baseline due to previous agents administered excluding alopecia and neurotoxicity (= 2 grade).

- History of autoimmune phenomena due to treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 antibodies, etc.) (= grade 3).

- Treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA4 antibodies, etc.) within 28 days of dosing of study drug.

- Have received any live vaccine within 28 days prior to study treatment.

- Known sensitivity to or history of allergic reactions to any of the investigational drugs or known hypersensitivity to Chinese hamster ovary cell products.

- History of severe allergic anaphylactic reactions to chimeric, human or humanized antibodies, or fusion proteins.

- Has active autoimmune disease that requires or has required systemic immunosuppressive treatment in the past 2 years.

- Presence of any tissue or organ allograft, regardless of need for immunosuppression, including corneal allograft. Patients with a history of allogeneic hematopoietic stem cell transplant will be excluded.

- Has a diagnosis of immunodeficiency.

- Systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 7 days prior to study drug administration.

- Symptomatic interstitial lung disease.

- Active or untreated brain metastases or leptomeningeal metastases.

- Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, different metastatic cancer than the one leading to study enrollment, or psychiatric illness/social situations that would limit compliance with study requirements.

Einschlusskriterien zur Erfassung im Register für Lebertumoren bei Kindern und Jugendlichen:
- Alle Patienten von 0 bis 20 Jahren mit einem primären (maligne und benigne) Lebertumor, die im Bereich der GPOH diagnostiziert und behandelt werden, sollen in das Register eingeschlossen werden.
- Die schriftliche Einwilligung des Patienten bzw. des Sorgeberechtigten zur Weitergabe, Speicherung und Auswertung personenbezogener Daten muss vorliegen.
- Hinweis: Bei Behandlung eines Patienten innerhalb einer anderen GPOH Studie bzw. Register, wie z. B. Lebersarkome – CWS-Register SoTiSaR, CWS-2007-HR, Keimzelltumoren - MAKEI 96, Rhabdoidtumoren – EU-RHAB sollte dieser in der jeweiligen Studie gemeldet werden, es erfolgt keine Datenerfassung in diesem Register.

For inclusion in the study, patients should fulfill the following criteria:

1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent, data processing consent (GDPR) and any locally required authorization (European Union [EU] Data Privacy Directive) obtained from the patient/legal representative prior to performing any protocol related procedures, including screening evaluations.

2. Age >=18 years at the time of study entry

3. Body weight >30 kg.

4. Confirmed HCC based on histopathological findings from tumor tissues.

5. Must not have received prior systemic therapy for HCC.

6. Not eligible for locoregional therapy for unresectable HCC. For patients who progressed after locoregional therapy for HCC, locoregional therapy must have been completed >=28 days prior to the baseline scan for the current study.

7. Barcelona Clinic Liver Cancer (BCLC) stage B (that is not eligible for locoregional therapy) or stage C (refer to Appendix C)

8. Child-Pugh Score class A. (refer to Table 8)

9. ECOG performance status of 0 or 1 at enrollment (refer to section 5.2.6)

10. Patients with HBV infection, characterized by positive hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibodies (anti-HBcAb) with detectable HBV DNA (>=10 IU/ml or above the limit of detection per local or central lab standard), must be treated with antiviral therapy, as per institutional practice, to ensure adequate viral suppression (HBV DNA <=2000 IU/mL) prior to enrollment. Patients must remain on antiviral therapy for the study duration and for 6 months after the last dose of study medication. Patients who test positive for anti-hepatitis B core
(HBc) with undetectable HBV DNA (<10 IU/ml or under the limit of detection per local or central lab standard) do not require anti-viral therapy prior to enrollment.
These subjects will be tested at every cycle to monitor HBV DNA levels and initiate antiviral therapy if HBV DNA is detected (>=10 IU/ml or above the limit of detection per local or central lab standard). HBV DNA detectable subjects must initiate and remain on antiviral therapy for the study duration and for 6 months after the last dose of study medication.

11. Patients with HCV infection must have confirmed diagnosis of HCV characterized by the presence of detectable HCV RNA or anti-HCV antibody upon enrollment (management of this disease is per local institutional practice).

12. At least 1 measurable lesion, not previously irradiated, that can be accurately measured at baseline as =10 mm in the longest diameter (except lymph nodes, which must have a short axis >=15 mm) with computerized tomography (CT) or magnetic resonance imaging (MRI), and that is suitable for accurate repeated measurements as per RECIST 1.1 guidelines. A lesion which progressed after previous ablation or TACE could be measurable if it meets these criteria.

13. Adequate organ and marrow function, as defined below. Criteria “a, “b, “c, and “f cannot be met with transfusions, infusions, or growth factor support administered within 14 days of starting the first dose.

a. Hemoglobin >=9 g/dL
b. Absolute neutrophil count >=1500/µL
c. Platelet count >=75000/µL
d. Total bilirubin (TBL) <=2.0x upper limit of normal (ULN)
e. AST and ALT <=5xULN
f. Albumin >=2.8 g/dL
g. International normalized ratio (INR) <=1.6. Note: INR prolongation due to anticoagulants for prophylaxis (e.g., atrial fibrillation) in patients without liver cirrhosis could be exception.
h. Calculated creatinine clearance >=50 mL/minute as determined by Cockcroft-Gault (using actual body weight) or 24-hour urine creatinine clearance
i. Urine dipstick for proteinuria < 2+ (within 7 days prior to initiation of study treatment), unless a subsequent 24-hour urine collection demonstrates < 1 g of protein in 24 hours.

14. Evidence of post-menopausal status or negative serum pregnancy test for female pre-menopausal patients. Women will be considered post-menopausal as described in Section 3.8.

15. Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.

16. Must have a life expectancy of at least 12 weeks

Patients should not enter the study if any of the following exclusion criteria are fulfilled:

1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).

2. Previous study drug(s) assignment in the present study.

3. Concurrent enrollment in another clinical study, unless it is an observational (non interventional) clinical study or during the follow-up period of an interventional study

4. Participation in another clinical study with an investigational product during the last 4 weeks or 5 half-lives of the respective drug/IMP, whichever is longer.

5. Any unresolved toxicity National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE) Grade =2 from previous anticancer therapy with the exception of
alopecia, vitiligo, and the laboratory values defined in the inclusion criteria:

- Patients with Grade >=2 neuropathy will be evaluated on a case-by-case basis after consultation with the Study Physician.
- Patients with irreversible toxicity not reasonably expected to be exacerbated by treatment with durvalumab or tremelimumab may be included only after consultation with the Study
Physician.

6. Any concurrent chemotherapy, study drug, or biologic or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable.

7. Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.

8. Radiotherapy treatment to more than 30% of the bone marrow or with a wide field of radiation within 28 days of the first dose of study drug(s).

9. Major surgical procedure or significant traumatic injury (as defined by the Investigator) within 28 days prior to the first dose of study drug(s), abdominal surgery, abdominal
interventions, or significant abdominal traumatic injury within 60 days prior to randomization or anticipation of need for major surgical procedure during the course of the study or nonrecovery from side effects of any such procedure. Note: Local surgery of isolated lesions for palliative intent is acceptable.

10. History of allogeneic organ transplantation (e.g., liver transplant).

11. History of hepatic encephalopathy within past 12 months or requirement for medications to prevent or control encephalopathy (e.g., no lactulose, rifaximin, etc if used for purposes of hepatic encephalopathy).

12. Clinically meaningful ascites, defined as any ascites requiring non-pharmacologic intervention (e.g., paracentesis) to maintain symptomatic control, within 6 months prior to the first scheduled dose. Subjects on stable doses of diuretics for ascites for >=2 months are eligible.

13. Patients with main portal vein thrombosis (i.e., thrombosis in the main trunk of the portal vein, with or without blood flow) on baseline imaging.

14. Patient currently exhibits symptomatic or uncontrolled hypertension defined as diastolic blood pressure >90 mmHg or systolic blood pressure >140 mmHg.

15. Any condition interfering with swallowing pills, uncontrolled diarrhea, or other contraindication to oral therapy.

16. Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease [e.g., colitis or Crohn's disease], diverticulitis [with the exception of
diverticulosis], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome [granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis,
uveitis, etc]). Patients without active disease in the last 5 years are excluded unless discussed with the Study Physician and considered appropriate for study participation.

The following are exceptions to this criterion:

a) Patients with vitiligo or alopecia
b) Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement
c) Any chronic skin condition that does not require systemic therapy
d) Patients with celiac disease controlled by diet alone

17. Patients co-infected with HBV and HCV, or co-infected with HBV and hepatitis D virus (HDV). HBV positive (presence of HBsAg and/or anti-HBcAb with detectable HBV DNA);
HCV positive (presence of anti-HCV antibodies); HDV positive (presence of anti- HDV antibodies).

18. Uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris,
cardiac arrhythmia, ILD, serious chronic GI conditions associated with diarrhea, inferior vena cava thrombosis, or psychiatric illness/social situations that would limit compliance with
study requirement, substantially increase the risk of incurring AEs, or compromise the ability of the patient to give written informed consent.

19. History of another primary malignancy except for:
- Malignancy treated with curative intent and with no known active disease =5 years before the first dose of study drug(s) and of low potential risk for recurrence
- Patients with a history of prostate cancer of stage =T2cN0M0 without biochemical recurrence or progression and who in the opinion of the Investigator are not deemed to require active intervention.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated carcinoma in situ without evidence of disease

20. History of leptomeningeal carcinomatosis.

21. History of, or current, brain metastases or spinal cord compression. Patients with suspected brain metastases at screening should have an MRI (preferred) or CT, each preferably with IV contrast of the brain prior to study entry.

22. Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) =470 ms calculated from 3 ECGs (within 15 minutes at 5 minutes apart).

23. Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC.

24. History of active primary immunodeficiency.

25. Known to have tested positive for human immunodeficiency virus (HIV) (positive HIV 1/2 antibodies) or active tuberculosis infection (clinical evaluation that may include clinical
history, physical examination and radiographic findings, or tuberculosis testing in line with local practice).

26. Current or prior use of immunosuppressive medication within 14 days before the first dose of study drug(s). The following are exceptions to this criterion:

a) Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection)
b) Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent
c) Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)

27. Receipt of live attenuated vaccine within 30 days prior to the first dose of study drug(s). Note: Patients, if enrolled, should not receive live vaccine while receiving study drug(s) and up to 30 days after the last dose of study drug(s).

28. Major gastrointestinal bleeding within 4 weeks prior to randomization.

29. Patients with untreated or incompletely treated varices with bleeding or high-risk for bleeding. Patients must undergo an esophagogastroduodenoscopy (EGD), and all size of
varices (small to large) must be assessed and treated per local standard of care prior to enrollment. Patients who have undergone an EGD within 6 months prior to randomization do
not need to repeat the procedure. Those who have received banding and/or sclerotherapy and with no bleeding event within the prior 6 months are eligible provided that a re-endoscopy is performed and that varices remained obliterated, minimal or Grade I

30. Significant vascular disease including aortic aneurysm requiring surgical repair or peripheral arterial thrombosis with 6 months prior to randomization

31. History of abdominal or tracheoesophageal fistula or gastrointestinal perforation, or intra abdominal abscess within 6 months prior to randomization.

32. History or clinical signs of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding. Evidence of abdominal free air that is not explained by paracentesis or recent surgical procedure

33. Evidence of bleeding diathesis or significant coagulopathy

34. Severe, non-healing or dehisced wound, active ulcer, or untreated bone fracture

35. Current or recent (within 10 days of randomization) use of acetylsalicyclic acid (> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol

36. Current or recent (within 10 days prior to randomization) use of full-dose oral or parenteral anticoagulants or thrombolytic agents for therapeutic purpose Prophylactic anticoagulation for the patency of venous access devices is allowed provided the activity of the agent results in an INR < 1.5 x ULN and aPTT is within normal limits within 14 days prior to randomization. Prophylactic use of low molecular-weight heparin is allowed.

37. Chronic daily treatment with a nonsteroidal anti-inflammatory drug (NSAID). Occasional use of NSAIDs for the symptomatic relief of medical conditions such as headache or fever is allowed.

38. Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 3 days prior to the first dose of bevacizumab

39. Female patients who are pregnant or breastfeeding, or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 90 days after the last dose of durvalumab monotherapy or 180 days after the last dose of durvalumab plus tremelimumab combination therapy or bevacizumab therapy

40. Prior randomization or treatment in a previous durvalumab and/or tremelimumab clinical study regardless of treatment arm assignment. For procedures for withdrawal of incorrectly enrolled patients, see Section 3.4.

1. Patients diagnosed with cancer

2. Patients planned to undergo or undergoing neoadjuvant treatment before planned curative resection

3. Adult patients (>= 18 years of age)

4. Written informed consent

5. Ability to understand character and individual consequences of the clinical trial

Additional for the online program

6. Stable internet connection

7. Laptop of similar

8. Poultieces utensils and utensils for the other applications

9. Sports mat or similar

1. Participation in another interventional trial with interference on intervention and outcome of this trial

2. Immobility or inability to walk unaided

3. Expected lack of compliance

- Patientinnen und Patienten, die eine viszeralchirurgische Operation mit kurativer In-tention aufgrund eines primären oder sekundären Malignom erhalten

- vorliegender Tumorboardbeschluss

- Alter = 18 Jahre

- Mündliche und schriftliche Einwilligungserklärung

- Schwangerschaft

- ASA = 4

- Geistige Einschränkung, welche eine Erfassung von Wesen, Art und Umfang des For-schungsprojekt verhindert

- Zu erwartende fehlende Wahrnehmung der Empfehlungen

- Fehlende Einwilligungsfähigkeit

- Teilnahme an einer anderen Studie, die das Studienergebnis beeinträchtigt

- Age equal to or greater than 18 years
- Patients undergoing robotic liver surgery for benign or malignant lesions
- Written informed consent

- ASA = 4
- Patients requiring vascular reconstruction and/or extrahepatic resections
- Impaired mental state or language barrier
- Suspected lack of compliance